Cargando…
Contribution of Aging, Obesity, and Microbiota on Tumor Immunotherapy Efficacy and Toxicity
Cancer immunotherapy has entered the forefront of cancer treatment, but major challenges still exist, such as the limited proportion of patients that respond to treatment and treatment-related toxicity. Therefore, biomarkers to predict which patients will benefit from therapy without major side effe...
Autores principales: | Baiden-Amissah, Regina E. M., Tuyaerts, Sandra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678743/ https://www.ncbi.nlm.nih.gov/pubmed/31340438 http://dx.doi.org/10.3390/ijms20143586 |
Ejemplares similares
-
Endometrial Cancer Molecular Characterization: The Key to Identifying High-Risk Patients and Defining Guidelines for Clinical Decision-Making?
por: Baiden-Amissah, Regina Esi Mensimah, et al.
Publicado: (2021) -
Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy
por: Tuyaerts, Sandra, et al.
Publicado: (2018) -
Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy
por: Vanderstraeten, Anke, et al.
Publicado: (2014) -
Balancing Cancer Immunotherapy Efficacy and Toxicity
por: Johnson, Douglas B., et al.
Publicado: (2020) -
The Role of Gut Microbiota in Tumor Immunotherapy
por: Wu, Miao, et al.
Publicado: (2021)